Connaught Laboratories Limited

Aventis Pasteur Limited

Sanofi Pasteur Inc.

Other

University of Alberta

University of Toronto

Washington University

Sanifo Pasteur Limited

Aventis Pasteur Limited/aventus Pasteur Limitee

Pasteur Merieux Connaught Canada

Sanofi Pasteur Limited/sanofi Pasteur Limitee

Pele Chong

Michel Henri Klein

Dwo Yuan Charles Sia

Mary Elizabeth Ewasyshyn

Sheena M Loosmore

Yan-Ping Yang

Mary E Ewasyshyn

Benjamin Rovinski

Robin E Harkness

Run-Pan Du

Raymond P Oomen

Shi-Xian Cao

Fei-Long Yao

Roy Persson

Anthony Bernard Schryvers

Gavin Ross Zealey

Ali Kandil

Stephen A Cockle

Andrew D Murdin

Scott Gray-Owen

Charles D Sia

Xiaomao Li

Joel E Haynes

Shi Xian Cao

Heather A Boux

Raafat Emil Fahim

Suryaprakash Sambhara

Reza Khayyam Yacoob

Lisa E Myers

Kenneth K Sokoll

George A Cates

Glen D Armstrong

Randy J Read

Bart Hazes

Ken Sasaki

Sonia E Sanhueza

Penelope E Stein

Gail E Jackson

Yan Ping Yang

Larry U Tan

Anne-Marie Bonneau

Barry Ian Caplan

John Vose

Naveen N Anand

Bruno Flesselles

Lucy Gisonni

Wayne Thomas

Olive A James

James Tartaglia

Brian H Barber

Jorge Filmus

Robert S Munson, Jr

Patrick McVerry

Emil F Pai

Mary E Ewashysyn

Dwo Yuan Sia

Diane M Gajewczyk

Arthur Pedyczak

Alf Lindberg

Judith E Caterini

Raafat Emil Fahmy Fahim

Quijun Wang

Mark Parrington

Charles D Y Sia

Luis Barreto

Raafat E F Fahim

John Thipphawong

Susan Grass

Gail E D Jackson

Larry U L Tan

Alison L Symington

Ursula McGuiness

Dwe Yuan Sia

Dwo Yan Charles Sia

Robert Tolan

David Burt

Andrew Herbert

John R Vose

Leslie Boux

Anton Novak

George C Cates

Dw&oslash; Yuan Charles Sia

Phillipe Moingeon

Sheena May Lossmore

Stephen Anthony Cockle

Heather Anne Boux

Raafat EF Fahim

Recombinant production of Hia protein, in full-length and N-terminally truncated forms, of non-typeable strains of, is described. The nucleic acid and deduced amino acid sequences of Hia genes of various strains of non-typeable and type calso are described.

[object Object]

Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.

Chimeric immunogens

The crystal structure of the Fab' fragment of Mab 2F5, a potent neutralizer of both laboratory strains and primary clinical isolates of most clades of HIV-1, both uncompleted and complexed with the largely conserved peptide sequence ELDKWAS of the viral envelope protein gp41, has been elucidated and the characteristics of peptide-protein interactions determined. Having regard to such determination, the peptide-mimetics are constrained in the three-dimensional structure to provide an increased immunogenicity to the epitope sequence.

Fab-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5

Purified and isolated nucleic acid molecules are provided which encode Tbp2 proteins ofstrains M35, 3 and LES1. The nucleic acid sequence may be used to produce recombinant Tbp2 proteins of the strain offree of other proteins of thestrain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules may be used in the diagnosis of infection.

Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H activity of the pol gene product through genetic manipulation of the gag and pol genes. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis.

Retrovirus-like particles made non-infectious by a plurality of mutations

An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using &#x3b2;-propiolactone, a non-ionic detergent, particularly n-octyl-&#x3b1;-D-glucopyranoside and n-octyl-&#x3b2;-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.

Inactivated respiratory syncytial viral vaccines

Immunogenic compositions for administration to adults, particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and by influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition, when formulated as a vaccine for in vivo administration, do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant.

Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation

Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain ofor a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

Transferrin receptor genes

A method of generating an HIV-specific cytotoxic T-cell response in a host involves an initial administration of a T-helper molecule to the host to prime T-helper cells of the immune system of the host and a subsequent administration to the host of a mixture of the T-helper molecule and a T-cell inducing HIV-derived molecule to generate an HIV-specific T-cell response in the host.

HIV-specific cytotoxic T-cell responses

A modulated immune response to an antigen is achieved by coadministering the antigen and a genetically-detoxifiedholotoxin, particularly one retaining its immunogenicity, to a host. The modulated immune response enables immunogenic compositions, including multivalent pediatric vaccines such as DTP, to be provided which produce a modulated immune response in the absence of extrinsic adjuvants such as alum. The adjuvanting effect achieved by the genetically-detoxifiedholotoxin enables at least the same level of adjuvanting effect to be achieved as previously attained by alum, without the undesirable side effects thereof.

Proteinaceous adjuvants

Growing community of inventors

Willowdale, Canada

Michel Henri Klein